Zealand Pharma received an undisclosed milestone payment from Wyeth for the advancement of an orally available gap junction modifier ZP1609 (GAP-134) into Phase I trials in the U.S. This is the second gap junction modifier in clinical trials developed by the two companies. ZP1609 has shown pharmacological effects in animal models of both ventricular and atrial arrhythmias, and with its oral formulation, the molecule represents a novel example for the potential prevention of cardiac arrhythm...